Standout Papers

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carci... 2018 2026 2020 2023 322
  1. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials (2018)
    Wenfeng Fang, Yunpeng Yang et al. The Lancet Oncology

Immediate Impact

3 by Nobel laureates 10 from Science/Nature 73 standout
Sub-graph 1 of 22

Citing Papers

Immune-related adverse events of immune checkpoint inhibitors: a review
2023 Standout
Hallmarks of aging: An expanding universe
2023 Standout
13 intermediate papers

Works of Xiaohui He being referenced

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
2018 Standout
SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol
2009

Author Peers

Author Last Decade Papers Cites
Xiaohui He 970 800 315 126 1.8k
Wen-Qi Jiang 1291 792 385 76 2.0k
Jung Yong Hong 1147 588 582 189 2.2k
Lukas Weiß 682 451 225 95 1.5k
Yan Gao 668 511 125 112 1.6k
Feng‐Hua Wang 1485 321 828 124 2.8k
Simon Thézenas 1644 345 770 117 2.9k
Ye Guo 980 401 379 205 2.2k
Florian Clatot 679 172 393 99 1.5k
Yan Qin 754 462 392 129 1.8k
Su‐Jin Shin 911 295 820 148 2.0k

All Works

Loading papers...

Rankless by CCL
2026